Business
Dyadic Reports First Quarter 2025 Financial Results and Highlights of Recent Company Progress
Expanded life science and industrial portfolio with six additional life science products in developmentAdvances toward commercialization of functional recombinant solutions for cell culture media, nucleic and industrial enzyme marketsUp to $4.5 million research grant awarded from the Coalition for Epidemic Preparedness (CEPI)Launched research for $3.0 million Gates Foundation grant for malaria and RSV antibody programsSelected to participate in the inaugural meeting of the "European Vaccines Hub
About this update from Dyadic International, Inc.
[{"type":"image","alt":"Dyadic International, Inc.","displaySize":"","headline":null,"caption":"Dyadic International, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":295,"height":229,"url":"https://media.zenfs.com/en/globenewswire.com/346a61dbf291488ea30b6fd65e81e681"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gy0FmjKeMiJzIWa7r133nQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMyNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/346a61dbf291488ea30b6fd65e81e681","width":295,"height":229}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Expanded life science and industrial portfolio with six additional life science products in development","length":103,"tagName":"p"}]},{"val":[{"type":"text","content":"Advances toward commercialization of functional recombinant solutions for cell culture media, nucleic and industrial enzyme markets","length":131,"tagName":"p"}]},{"val":[{"type":"text","content":"Up to $4.5 million research grant awarded from the Coalition for Epidemic Preparedness (CEPI)","length":93,"tagName":"p"}]},{"val":[{"type":"text","content":"Launched research for $3.0 million Gates Foundation grant for malaria and RSV antibody programs","length":95,"tagName":"p"}]},{"val":[{"type":"text","content":"Selected to participate in the inaugural meeting of the "European Vaccines Hub for Pandemic Readiness (EVH)" project.","length":127,"tagName":"p"}]},{"val":[{"type":"text","content":"Scientific Pre-Publication – “Expression and Characterization of SARS-CoV-2 Spike Protein in Thermothelomyces heterothallica C1”","length":128,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash, cash equivalents and investment-grade securities of $7.4 million as of March 31, 2025","length":91,"tagName":"p"}]},{"val":[{"type":"text","content":"Financial results and business update conference call scheduled for 5:00 pm ET today","length":84,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":852,"olType":false},{"type":"text","content":"JUPITER, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company specializing in the development of functional recombinant solutions and proprietary production strains to manufacture large quantities of precision-engineered proteins and enzymes for use in life sc...